Cardiac sarcoidosis
diseaseOn this page
Also known as heart sarcoidosissarcoidosis of heart
Summary
Cardiac sarcoidosis (MONDO:0001707) is a disease and 34 clinical trials. Top therapeutic interventions include anakinra, edotreotide gallium ga-68, and prednisone. A subtype of non-familial restrictive cardiomyopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 34
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cardiac sarcoidosis |
| Mondo ID | MONDO:0001707 |
| DOID | DOID:13405 |
| NCIT | C35589 |
| SNOMED CT | 75403004 |
| UMLS | C0392077 |
| MedGen | 140260 |
| GARD | 0022992 |
| Anatomy (UBERON) | UBERON:0000948 |
| Is cancer (heuristic) | no |
Also known as: heart sarcoidosis · sarcoidosis of heart
Disease family
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › cardiomyopathy › intrinsic cardiomyopathy › restrictive cardiomyopathy › non-familial restrictive cardiomyopathy › cardiac sarcoidosis
Related subtypes (6): hypereosinophilic syndrome, wild type ATTR amyloidosis, tropical endomyocardial fibrosis, Loeffler endocarditis, AL amyloidosis, AA amyloidosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 34.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 24 |
| PHASE2 | 7 |
| PHASE4 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01210677 | PHASE4 | WITHDRAWN | Cardiac Sarcoidosis Response To Steroids Trial |
| NCT03549598 | PHASE4 | COMPLETED | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis |
| NCT03593759 | PHASE3 | RECRUITING | Cardiac Sarcoidosis Randomized Trial |
| NCT05499637 | PHASE2 | RECRUITING | [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation |
| NCT06660732 | PHASE2 | RECRUITING | Rilonacept in Subjects With Cardiac Sarcoidosis |
| NCT06868381 | PHASE2 | NOT_YET_RECRUITING | A Trial of Baricitinib in Patients With Cardiac Sarcoidosis |
| NCT07159074 | PHASE2 | RECRUITING | Repurposing Tilmanocept for Cardiac Sarcoidosis |
| NCT03103490 | PHASE2 | TERMINATED | 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation |
| NCT04017936 | PHASE2 | COMPLETED | Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis |
| NCT04758650 | PHASE2 | UNKNOWN | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis |
| NCT01477359 | Not specified | RECRUITING | Cardiac Sarcoidosis Multi-Center Prospective Cohort |
| NCT03049254 | Not specified | RECRUITING | Mayo AVC Registry and Biobank |
| NCT04737317 | Not specified | RECRUITING | Diagnostic Criteria in Cardiac Sarcoidosis |
| NCT04774549 | Not specified | ACTIVE_NOT_RECRUITING | Inflammatory Cardiomyopathy Bern Registry |
| NCT05793398 | Not specified | NOT_YET_RECRUITING | Biomaterial Collection - and Analysis in Cardiac Sarcoidosis |
| NCT05954507 | Not specified | RECRUITING | Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis |
| NCT06131112 | Not specified | RECRUITING | Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis |
| NCT06409585 | Not specified | RECRUITING | Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition |
| NCT06510894 | Not specified | RECRUITING | Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression |
| NCT07029295 | Not specified | NOT_YET_RECRUITING | Evaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation |
| NCT07336394 | Not specified | RECRUITING | Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques |
| NCT07604220 | Not specified | NOT_YET_RECRUITING | Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS) |
| NCT01729169 | Not specified | COMPLETED | Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET |
| NCT01764191 | Not specified | APPROVED_FOR_MARKETING | 18F-FDG PET Imaging in Cardiac Sarcoidosis |
| NCT02017522 | Not specified | TERMINATED | Non-Invasive Characterization in Cardiac Sarcoidosis |
| NCT02812849 | Not specified | WITHDRAWN | Somatostatin Receptor Imaging in Cardiac Sarcoidosis |
| NCT03057002 | Not specified | COMPLETED | UTSW HP [13-C] Pyruvate Injection in HCM |
| NCT03599414 | Not specified | COMPLETED | CASPA: CArdiac Sarcoidosis in PApworth |
| NCT03705884 | Not specified | COMPLETED | PET/MR Imaging In Patients With Cardiac Sarcoidosis |
| NCT03746847 | Not specified | COMPLETED | PET Imaging in Patients With Suspected Cardiac Sarcoidosis |
| NCT03902223 | Not specified | COMPLETED | Routine Cardiac Screening in Sarcoidosis Patients |
| NCT03923049 | Not specified | TERMINATED | Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis |
| NCT04206163 | Not specified | COMPLETED | Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis |
| NCT05145023 | Not specified | COMPLETED | Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ANAKINRA | 4 | 1 |
| EDOTREOTIDE GALLIUM GA-68 | 4 | 1 |
| PREDNISONE | 4 | 1 |
| RILONACEPT | 4 | 1 |
| SOTAGLIFLOZIN | 4 | 1 |
| FLORILGLUTAMIC ACID F-18 | 2 | 1 |
| CHEMBL15720 | 0 | 1 |
| CHEMBL5220618 | 0 | 1 |
| CHEMBL454299 | 0 | 1 |
| CHEMBL5202047 | 0 | 1 |